Toll Free: 1-888-928-9744

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 35 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H1 2016', provides in depth analysis on N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted pipeline therapeutics. 

The report provides comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
- The report reviews N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) Overview 6 Therapeutics Development 7 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Stage of Development 7 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Therapy Area 8 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Indication 9 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Products Glance 10 Early Stage Products 10 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Companies 11 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Products under Development by Universities/Institutes 13 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Molecule Type 18 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in Therapeutics Development 20 Bristol-Myers Squibb Company 20 CohBar, Inc. 21 Polyphor Ltd. 22 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles 23 Drugs to Agonize FPR-2 for Inflammation - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Humanin - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 NCP-70X - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Peptides for Alzheimer's Disease and Type II Diabetes - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Synthetic Peptides to Agonize FPR1/2 for Immunology and Infectious Disease - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Synthetic Peptides to Antagonize FPR1/2 for Immunology and Infectious Disease - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Projects 31 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products 32 N-Formyl Peptide Receptor 2 (FMLP-Related Receptor I or FMLP-R-I or Formyl Peptide Receptor-Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Featured News & Press Releases 33 May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Bristol-Myers Squibb Company, H1 2016 20 Pipeline by CohBar, Inc., H1 2016 21 Pipeline by Polyphor Ltd., H1 2016 22 Dormant Projects, H1 2016 31 Discontinued Products, H1 2016 32


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Mechanism of Actions, H1 2016 16 Number of Products by Stage and Mechanism of Actions, H1 2016 16 Number of Products by Molecule Types, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify